- Home
- CRDL vs DOUG Comparison
CRDL vs DOUG Comparison
Compare CRDL & DOUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- DOUG
- Stock Information
- Founded
- CRDL 2017
- DOUG 1911
- Country
- CRDL Canada
- DOUG United States
- Employees
- CRDL N/A
- DOUG N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- DOUG Building operators
- Sector
- CRDL Health Care
- DOUG Real Estate
- Exchange
- CRDL Nasdaq
- DOUG Nasdaq
- Market Cap
- CRDL 125.7M
- DOUG 146.0M
- IPO Year
- CRDL N/A
- DOUG N/A
- Fundamental
- Price
- CRDL $1.28
- DOUG $1.65
- Analyst Decision
- CRDL Strong Buy
- DOUG
- Analyst Count
- CRDL 3
- DOUG 0
- Target Price
- CRDL $9.00
- DOUG N/A
- AVG Volume (30 Days)
- CRDL 391.0K
- DOUG 1.1M
- Earning Date
- CRDL 11-14-2024
- DOUG 11-07-2024
- Dividend Yield
- CRDL N/A
- DOUG N/A
- EPS Growth
- CRDL N/A
- DOUG N/A
- EPS
- CRDL N/A
- DOUG N/A
- Revenue
- CRDL N/A
- DOUG $966,442,000.00
- Revenue This Year
- CRDL N/A
- DOUG $5.28
- Revenue Next Year
- CRDL N/A
- DOUG $16.40
- P/E Ratio
- CRDL N/A
- DOUG N/A
- Revenue Growth
- CRDL N/A
- DOUG 1.86
- 52 Week Low
- CRDL $0.79
- DOUG $1.00
- 52 Week High
- CRDL $3.12
- DOUG $3.16
- Technical
- Relative Strength Index (RSI)
- CRDL 26.78
- DOUG 33.67
- Support Level
- CRDL $1.27
- DOUG $2.23
- Resistance Level
- CRDL $1.46
- DOUG $2.47
- Average True Range (ATR)
- CRDL 0.10
- DOUG 0.18
- MACD
- CRDL -0.00
- DOUG -0.09
- Stochastic Oscillator
- CRDL 3.33
- DOUG 5.00
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About DOUG Douglas Elliman Inc.
Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.